Doxorubicin (hydrochloride)

Doxorubicin (hydrochloride)

• CAS Number: 25316-40-9
• UNSPSC Description: Doxorubicin (Hydroxydaunorubicin) hydrochloride, a cytotoxic anthracycline antibiotic, is an anti-cancer chemotherapy agent. Doxorubicin hydrochloride is a potent human DNA topoisomerase I and topoisomerase II inhibitor with IC50s of 0.8 μM and 2.67 μM, respectively. Doxorubicin hydrochloride reduces basal phosphorylation of AMPK and its downstream target acetyl-CoA carboxylase. Doxorubicin hydrochloride induces apoptosis and autophagy[1][2][3].
• Target Antigen: ADC Cytotoxin; AMPK; Antibiotic; Apoptosis; Autophagy; Bacterial; HBV; HIV; Mitophagy; Topoisomerase
• Type: Natural Products
• Related Pathways: Antibody-drug Conjugate/ADC Related;Anti-infection;Apoptosis;Autophagy;Cell Cycle/DNA Damage;Epigenetics;PI3K/Akt/mTOR
• Applications: Cancer-Kinase/protease
• Field of Research: Cancer; Infection
• Assay Protocol: https://www.medchemexpress.com/Doxorubicin-hydrochloride.html
• Solubility: DMSO : 25 mg/mL (ultrasonic;warming;heat to 60°C)|H2O : 50 mg/mL (ultrasonic;warming;heat to 60°C)
• Smiles: COC1=C2C(C(C(C(O)=C(C[C@](C(CO)=O)(O)C[C@@H]3O[C@@]4([H])C[C@H](N)[C@H](O)[C@H](C)O4)C3=C5O)=C5C2=O)=O)=CC=C1.[H]Cl
• Molecular Weight: 579.98
• References & Citations: [1]John L. Nitiss, et al. Targeting DNA topoisomerase II in cancer chemotherapy.Nat Rev Cancer. 2009 May;9(5):338-50.|[2]Hee-KyungRhee,et al. Synthesis, cytotoxicity, and DNA topoisomerase II inhibitory activity of benzofuroquinolinediones. Bioorg Med Chem. 2007 Feb 15;15(4):1651-8.|[3]P D Foglesong, et al. Doxorubicin inhibits human DNA topoisomerase I. Cancer Chemother Pharmacol. 1992;30(2):123-5.|[4]Nesstor Pilco-Ferreto, et al. Influence of doxorubicin on apoptosis and oxidative stress in breast cancer cell lines. Int J Oncol. 2016 Aug;49(2):753-62.|[5]Regine Lüpertz, et al. Dose- and time-dependent effects of doxorubicin on cytotoxicity, cell cycle and apoptotic cell death in human colon cancer cells. Toxicology. 2010 May 27;271(3):115-21.|[6]Penelope D Ottewell, et al. Antitumor effects of doxorubicin followed by zoledronic acid in a mouse model of breast cancer. J Natl Cancer Inst. 2008 Aug 20;100(16):1167-78.|[7]Koda LY, Van der Kooy D. Doxorubicin: a fluorescent neurotoxin retrogradely transported in the central nervous system. Neurosci Lett. 1983 Mar 28;36(1):1-8. doi: 10.1016/0304-3940(83)90476-7. PMID: 6190113. 9|[8]Kauffman MK, Kauffman ME, Zhu H, Jia Z, Li YR. Fluorescence-Based Assays for Measuring Doxorubicin in Biological Systems. React Oxyg Species (Apex). 2016;2(6):432-439. doi: 10.20455/ros.2016.873. PMID: 29707647; PMCID: PMC5921830.|[9]Mirza A Z, Shamshad H. Preparation and characterization of doxorubicin functionalized gold nanoparticles[J]. European journal of medicinal chemistry, 2011, 46(5): 1857-1860.ACS Appl Mater Interfaces. 2020 Oct 21;12(42):47330-47341.|ACS Appl Mater Interfaces. 2022 Aug 24.|ACS Appl Mater Interfaces. 2024 Oct 8.|ACS Nano. 2020 Nov 24;14(11):15904-15918.|ACS Nano. 2024 Nov 1.|Acta Biomater. 2024 Dec 19:S1742-7061(24)00738-4.|Acta Pharmacol Sin. 2023 May 24.|Acta Pharmacol Sin. 2024 Jun 6.|Adv Funct Mater. 10 October 2021.|Adv Funct Mater. 23 October 2021.|Adv Healthc Mater. 2020 Nov;9(22):e2001633.|Adv Healthc Mater. 2021 Sep 8;e2101222.|Adv Sci (Weinh). 2020 Sep 28;7(21):2001364.|Advanced Therapeutics. 2021 Apr 14.|Am J Cancer Res. 2021 Apr 15;11(4):1428-1445.|Am J Physiol Cell Physiol. 2024 May 27.|Am J Transl Res. 2021 Sep 15;13(9):10112-10126.|Anal Chim Acta. 2024 Jan 25, 1287, 342110.|Angiogenesis. 2021 Jan 17.|Ann Transl Med. 2020 Dec;8(23):1570.|Anticancer Drugs. 2022 Mar 1;33(3):308-319.|Antioxid Redox Signal. 2024 Aug 30.|Antioxid Redox Signal. 2024 May 30.|Arab J Chem. July 2022, 103934.|Autophagy. 2021 Dec 10;1-19.|Autophagy. 2021 Mar 22;1-17.|Bioact Mater. 2024 May 11:38:384-398.|Biochem Biophys Res Commun. 2019 Dec 10;520(3):544-550.|Biochem Biophys Res Commun. 2020 Dec 10;533(3):304-312.|Biochem Biophys Res Commun. 2024 Aug 19:739:150568.|Biochem Biophys Res Commun. 2024 Jan 8:691:149314.|Bioengineered. 2022 Apr;13(4):9467-9481.|Biol Direct. 2023 Oct 9;18(1):63.|Biomacromolecules. 2022 Sep 14.|Biomater Adv. 17 October 2022, 213161.|Biomed Pharmacother. 2020 Oct;130:110534.|Biomed Pharmacother. 2021 May 29;140:111779.|Biomed Pharmacother. 2021 May;137:111378.|Biomed Pharmacother. 2021, 111308.|Biomed Pharmacother. 2021, 111531.|Biomed Pharmacother. 2024 Jul 19:178:117167.|Biomed Pharmacother. 2024 Mar 2:173:116353.|Biomed Pharmacother. 2024 Oct 14:180:117535.|bioRxiv. 2020 Jun.|bioRxiv. 2023 Feb 7.|bioRxiv. 2023 Jan 13.|bioRxiv. 2023 May 12.|bioRxiv. 2023 Sep 16.|bioRxiv. 2024 Aug 2:2024.08.02.606061.|bioRxiv. 2024 May 15.|bioRxiv. 2024 Nov 6:2024.11.04.621884.|bioRxiv. 2024 September 19.|Blood Sci. 2024 Jul 10;6(3):e00192.|Br J Pharmacol. 2024 Jul 3.|Braz J Med Biol Res. 2024 Jul 1:57:e13357.|Breast Cancer Res Treat. 2021 Jul 8.|Cancer Biol Med. 2021 Feb 15; 18(1): 184-198.|Cancer Biol Med. 2021 Feb.|Cancer Commun (Lond). 2024 Apr;44(4):469-490.|Cancer Immunol Immunother. 2024 Jul 2;73(9):177.|Cancer Lett. 2021 Aug 10;S0304-3835(21)00395-5.|Cancer Lett. 2022 Jun 28;536:215651.|Cancer Sci. 2022 Jun;113(6):2008-2021.|Cancers (Basel). 2021, 13(13), 3323.|Cancers (Basel). 2022, 14(3), 683.|Cell Death Differ. 2022 Jan 15.|Cell Death Dis. 2020 Sep 15;11(9):756.|Cell Death Dis. 2022 Aug 24;13(8):731.|Cell Death Dis. 2024 Jul 31;15(7):545.|Cell Death Dis. 2024 May 20;15(5):349.|Cell Death Discov. 2021 Aug 5;7(1):204.|Cell Metab. 2022 Feb 7;34(3):424-440.e7.|Cell Rep Med. 2024 May 29:101592.|Cell Rep. 2021 Aug 24;36(8):109568.|Cell Rep. 2023 Mar 20;42(3):112275.|Cell Rep. 2023, 42(1): 111916.|Cell Stem Cell. 2021 Sep 14;S1934-5909(21)00343-X.|Cell. 2024 Apr 25;187(9):2288-2304.e27.|Cell. 2024 Dec 26;187(26):7637-7654.e29.|Cells. 2022 Dec 29;12(1):145.|Cells. 2022, 11(17), 2642.|Cells. 2023, 12(1), 145.|Chem Biodivers. 2022 Sep 1.|Chem Biol Interact. 2024 Jul 31:400:111179.|Chem Eng J. 2020, 127874.|China Biotechnology. 2017, 37(4): 68-75.|Circ Heart Fail. 2021 Oct;14(10):e008220.|Colloid Interface Sci Commun. 2019 Jan;28:69-74. |Colloid Surface B. 2021, 111839.|Colloids Surf B Biointerfaces. 2018 Jul 10;171:176-185.|Colloids Surf B Biointerfaces. 2019 Jan 1;173:27-35.|Colloids Surf B Biointerfaces. 2024 Aug 5:244:114141.|Colloids Surf B Biointerfaces. 2024 May 3:239:113937.|Department of Pharmaceutical Sciences, University of Toronto. 2019 Oct.|Dev Cell. 2018 Sep 24;46(6):681-695.e5.|DNA Repair . 13 March 2022, 103319.|Drug Deliv Transl Res. 2023 Mar 27.|Drug Resist Updat. 2024 Sep 12:77:101151.|EBioMedicine. 2021 Jul;69:103456.|Elife. 2022 May 3;11:e69255.|Eur Heart J Open. 2023 Oct 9.|Eur J Pharm Biopharm. 2018 Aug;129:88-103.|Eur J Pharmacol. 2024 Jul 30:980:176865.|Expert Opin Drug Deliv. 2021 Mar 11.|FEBS Open Bio. 2021 Nov 14.|Free Radic Biol Med. 2019 Jan;130:557-567.|Free Radic Biol Med. 2021 Feb 1;163:141-152.|Free Radic Biol Med. 2023 Apr 24;S0891-5849(23)00378-7.|Free Radic Biol Med. 2024 Aug 5:S0891-5849(24)00587-2.|Free Radical Bio Med. 2021 Jan 6.|Front Cell Dev Biol. 2021 Dec 24;9:781792.|Front Endocrinol (Lausanne). 2018 Mar 22;9:120. |Front Oncol. 2024 Jul 19:14:1440650.|Genes Genomics. 2024 Oct 12.|Harvard Medical School LINCS LIBRARY|Heidelberg University. 2024.|Heliyon. 2023 Jul 13.|Heliyon.2024 May 29.|Hepatology. 2020 May;71(5):1660-1677. |Hereditas. 2023 Oct 31;160(1):36.|Hum Gene Ther. 2024 Aug 19.|Inorganica Chimica Acta. 468 (2017) 270-279.|Int Immunopharmacol. 2021 Oct 26;101(Pt A):108264.|Int Immunopharmacol. 2024 May 10:134:112197.|Int J Biol Macromol. 2024 Jul 4:133652.|Int J Biol Sci. 2021 Jul 25;17(12):3255-3267.|Int J Med Sci. 2021 Jan 1;18(2):325-334.|Int J Med Sci. 2024 Jul 8;21(9):1769-1782.|Int J Mol Med. 2025 Jan;55(1):10.|Int J Mol Sci. 2019 Mar 5;20(5). pii: E1125. |Int J Mol Sci. 2022 Nov 19;23(22):14385.|Int J Mol Sci. 2023 Dec 25, 25(1), 312.|Int J Mol Sci. 2024 Mar 7, 25(6), 3101.|Int J Nanomedicine. 2024 Jan 5.|Int J Nanomedicine. 2024 Jul 3:19:6717-6730.|Int J Oncol. 2023 Feb 8.|Int J Pharm. 2022 May 25;620:121761.|Int J Pharm. 2023 Feb 24;122779.|Int J Pharm. 2024 Feb 11:653:123894.|Int J Radiat Oncol Biol Phys. 2022 Jul 30;S0360-3016(22)02596-2.|Iran J Med Sci. 2024 Apr 30.|J Biochem Mol Toxicol. 2022 Apr 25:e23077.|J Biomater Sci Polym Ed. 2018 Aug;29(12):1482-1497. |J Biomater Sci Polym Ed. 2021 Mar 11;1-13.|J Bone Oncol. October 2021, 100391.|J Cardiovasc Transl Res. 2020 Jul 16. |J Cell Biol. 2023 Jan 2;222(1):e202202110.|J Cell Physiol. 2021 Apr 26.|J Colloid Interface Sci. 2024 Jul 15:676:378-395.|J Colloid Interface Sci. 2024 Jun 23:674:500-512.|J Control Release. 2019 Jun 26;307:247-260. |J Control Release. 2022 Feb 21;S0168-3659(22)00100-6.|J Ethnopharmacol. 2022 Aug 31;115676.|J Extracell Vesicles. 2022 Aug;11(8):e12255.|J Hematol Oncol. 2021 Oct 29;14(1):178.|J Immunother Cancer. 2022 Aug;10(8):e004006.|J Med Chem. 2023 Jul 6.|J Mol Med (Berl). 2019 Aug;97(8):1183-1193.|J Nanobiotechnology. 2023 Feb 10;21(1):50.|J Org Chem. 2021 Sep 16.|J Transl Med. 2021 Mar 21;19(1):117.|J Virol. 2021 May 26;JVI0076021.|Journal of New Chinese Medicine. 2016(7):278-282.|Lett Appl Microbiol. 2022 Feb 25.|Mater Chem Phys. 2021, 124596.|Mater Today Bio. 2023 Oct, 22, 100780.|Materials Today Chemistry. March 2022, 100637.|MedComm. 2021 Jun 3.|Mol Cancer. 2024 Jan 10;23(1):12.|Mol Cancer. 2024 May 9;23(1):83.|Mol Carcinog. 2021 Apr 18.|Mol Cell Biochem. 2021 Feb;476(2):1233-1243.|Mol Med Rep. 2020 Aug;22(2):915-925.|Mol Nutr Food Res. 2024 May 29:e2400123.|Mol Ther. 2019 May 8;27(5):1051-1065. |Nanoscale Res Lett. 2018 Nov 3;13(1):350. |Nanotheranostics. 2021 Jan 1;5(2):143-154.|Nanotheranostics. 2021; 5(2): 143-154.|Nat Cell Biol. 2020 Sep;22(9):1056-1063.|Nat Cell Biol. 2024 Jul 22.|Nat Commun. 2018 Oct 8;9(1):4139. |Nat Commun. 2023 Apr 13;14(1):2109.|Nat Commun. 2024 Jul 9;15(1):5761.|Nat Med. 2016 May;22(5):547-56. |Nat Prod Commun. 2024 Mar 20.|Nat Protoc. 2021 Jan;16(1):405-430.|Nature. 2023 Jun;618(7964):374-382.|Nature. 2024 Oct;634(8036):1229-1237.|Neuropharmacology. 2024 May 2:109981.|NPJ Breast Cancer. 2022 May 6;8(1):60.|Oncogene. 2022 Jun 30.|Oncotarget. 2017 Nov 24;8(67):111190-111212. |Oxid Med Cell Longev. 2022 Apr 5;2022:4740931.|Oxid Med Cell Longev. 2023 Jan 14;2023:9966355.|Patent. US20180185310A1.|Patent. US20180185346A1.|Patent. US20180185379A1.|Patent. US20180185386A1.|Patent. US20180185387A1.|Patent. US20180185388A1|Patent. US20180185389A1.|Patent. US20180193355A1.|Patent. US20200085841A1 |Patent. US20200345752A1.|Patent. US20210275477A1.|Patent. US20220016148A1.|Patent. US20230190773A1.|Patent. US20240245665A1.|Patent. US20240344035A1.|Pathol Res Pract. January 2022, 153735.|Pharmaceutics. 2024 Nov 25.|Pharmacol Res. 2021 Apr 30;169:105642.|Pharmacol Res. 2024 May 9:204:107208.|Phytochemistry. 2021 Jul 31;190:112892.|Phytomedicine. 2022 Jan 29;99:153964.|Phytomedicine. 2023 Jun 10, 154922.|Phytomedicine. 2023 Mar 10.|Phytomedicine. 2024 Oct 18:135:156155.|Phytomedicine. 2024 Sep 13:135:156051.|PLoS Pathog. 2020 Mar 24;16(3):e1008429.|Polym Bull (Berl). 30 September 2022.|Redox Biol. 2021 Aug 31;46:102120.|Res Sq. 2024 Dec 5:rs.3.rs-5278203.|Res Sq. 2024 Jul 11.|Res Sq. 2024 Sep 11.|Research Square Preprint. 2020 Jul.|Research Square Preprint. 2021 Nov.|Research Square Preprint. 2021 Sep.|Research Square Preprint. 2023 Nov 25.|Research Square Preprint. 2023 Sep 20.|Sci Adv. 2023 Mar 10;9(10):eadd8539.|Sci Transl Med. 2024 Apr 3;16(741):eadj5705.|Shock. 2023 Jul 1;60(1):100-109.|Signal Transduct Target Ther. 2023 Feb 3;8(1):51.|Signal Transduct Target Ther. 2024 Oct 16;9(1):273.|Small. 2023 Feb 7;e2205606.|Small. 2024 Jan 15:e2308265.|SSRN. 2023 Aug 14.|SSRN. 2023 Nov 28.|Ther Deliv. 2017 Mar;8(5):249-264.|Theranostics. 2020 May 17;10(15):6581-6598. |Thyroid. 2019 Jun;29(6):809-823. |TMR Modern Herbal Medicine. 2021 Jul.|Toxicol Appl Pharmacol. 2024 Aug 30:117082.|Transl Androl Urol. Jul 29, 2022.|Transl Oncol. 2021 Nov 22;15(1):101272.|Ulsan National Institute of Science and Technology. 2023 Aug.|Universiti Tunku Abdul Rahman. 2023 Sep 11.|University of Gothenburg. 2023 Jun 27.|University of Szeged. Department of Biochemistry and Molecular Biology Faculty of Science and Informatics. 2020 Nov.|ACS Omega. 2019 Jul 11;4(7):12036-12042.|Acta Biomater. 2020 Jun;109:229-243.|Acta Biomater. 2024 Apr 15:179:340-353.|Adv Healthc Mater. 2019 Sep;8(18):e1900543.|Adv Sci (Weinh). 2022 May;9(15):e2105894.|Adv Sci (Weinh). 2022 Oct;9(30):e2201210.|Adv Sci (Weinh). 2023 Mar 26;e2206007.|Am J Physiol Cell Physiol. 2023 Nov 27.|Anal Chem. 2022 Sep 19.|Antioxid Redox Signal. 2023 Jun 2.|Artif Cells Nanomed Biotechnol. 2023 Dec;51(1):120-130.|Asian J Pharm Sci. 2024 Jan 12, 100884.|BBA-Mol Cell Res. 2022: 119409.|Biochem Biophys Rep. 2024 Mar, 37, 101639.|Biochem Biophys Res Commun. 2019 Sep 24;517(3):538-544.|Biochem Biophys Res Commun. 2020 Jan 15;521(3):596-602.|Biochem Biophys Res Commun. 2023 Nov 18, 149244.|Biochem Biophys Res Commun. 2023 Nov 24, 149314.|Biochem Biophys Res Commun. 2024 Jan 25, 149582.|Biochem Pharmacol. 2020 Apr;174:113795.|Biochem Pharmacol. 2020 May;175:113888.|Biochem Pharmacol. 2023 Aug 25;115769.|Biochem Pharmacol. 2024 Mar 16:116142.|Biochem Pharmacol. 2020 May;175:113856.|Biochim Biophys Acta Mol Cell Res. 2022: 119411.|Biofabrication. 2022 Apr 13;14(3).|Biomacromolecules. 2023 Jan 13.|Biomaterials. 2023 Oct, 301, 122236.|Biomed Pharmacother. 2020 Mar;123:109803.|Biomed Pharmacother. 2023 Apr 13;162:114691.|Biomed Pharmacother. 2023 Apr 21;162:114733.|Biomed Pharmacother. 2023 Jan;157:114087.|Biomed Pharmacother. 2023 Oct 6:168:115654.|Biomolecules. 2022 Feb 12;12(2):299.|Bioorg Chem. 17 October 2022, 106206.|bioRxiv. 2023 Apr 14.|bioRxiv. 2023 Feb 27.|bioRxiv. 2023 Sep 5.|BMC Cancer. 2019 Jun 18;19(1):602. |Br J Pharmacol. 2022 Jan 18.|Breast Cancer Res Treat. 2023 May 19.|Breast Cancer Res. 2023 Oct 4;25(1):115.|Breast Cancer Res. 2024 Mar 19;26(1):48.|Cancer Biol Ther. 2024 Dec 31;25(1):2403197.|Cancer Cell Int. 2019 Jul 12;19:179. |Cancer Lett. 2022 Nov 30;216028.|Cancers (Basel). 2022, 14(13), 3068.|Cancers (Basel). 2023 Feb 1;15(3):930.|Carcinogenesis. 2022 Sep 30;bgac078.|Cell Biochem Funct. 2022 Apr 29.|Cell Biosci. 2022 Jan 6;12(1):6.|Cell Chem Biol. 2020 Nov 19;27(11):1359-1370.e8.|Cell Chem Biol. 2024 Jul 9:S2451-9456(24)00273-3.|Cell Commun Signal. 2024 Jun 13;22(1):325.|Cell Death Differ. 2022 Oct;29(10):1982-1995.|Cell Death Dis. 2019 Nov 25;10(12):887. |Cell Death Dis. 2022 Apr 5;13(4):305.|Cell Death Dis. 2024 Jan 18;15(1):66.|Cell Death Dis. 2019 Sep 11;10(9):668.|Cell Mol Neurobiol. 2022 Oct 20.|Cell Physiol Biochem. 2017;42(3):965-973.|Cell Res. 2018 Dec;28(12):1171-1185. |Cell Signal. 2017 May 1;36:108-116. |Cell Signal. 2023 Mar 14;110655.|Cell Stress Chaperones. 2022 Dec 13.|Chem Biol Interact. 2024 Feb 13:110904.|Chem Eng J. 15 October 2022, 137110.|Chronic Diseases Prevention Review. 2019 Feb.|Clin Cancer Res. 2020 Apr 15;26(8):2011-2021. |Clin Exp Pharmacol Physiol. 2023 Aug 13.|Clin Transl Med. 2024 Feb;14(2):e1586.|Clin Transl Oncol. 2023 Feb 27.|Commun Biol. 2022 Nov 26;5(1):1295.|Comput Biol Med. 2024 Jul 18:179:108901.|Eur J Med Chem. 2023 Nov 24, 115975.|Eur J Med Chem. 2023 Oct 5, 258, 115602.|Eur J Nucl Med Mol Imaging. 2024 Mar 16.|Eur J Pharm Sci. 2023 May 21;106472.|Eur J Pharmacol. 2024 Mar 27:176538.|Evid Based Complement Alternat Med. 2022 Sep 28;2022:7760945.|Exp Ther Med. 2023 May 16.|FASEB J. 2022 Sep;36(9):e22495.|FASEB J. 2023 Dec;37(12):e23284.|FASEB J. 2023 Jun;37(6):e22982.|Food Funct. 17th January 2022.|Food Funct. 2022 Aug 24.|Free Radic Biol Med. 2022 Oct 11;S0891-5849(22)00898-X.|Free Radic Biol Med. 2024 Jun 18:S0891-5849(24)00526-4.|Front Cell Dev Biol. 2021 May 31;9:661602.|Front Immunol. 2020 May 5;11:802.|Front Oncol. 2020 Mar 13;10:308.|Gels. 2022 Apr 12;8(4):237.|Gels. 2022, 8(9), 594.|Heliyon. 2024 June 28.|IEEE Access. 2023 May 31.|Infect Immun. 2019 Dec 17;88(1):e00697-19.|Int Immunopharmacol. 2022 Nov 26;114:109450.|Int Immunopharmacol. 2024 Aug 24:141:113010.|Int J Biol Sci. 2022 Apr 11;18(7):2882-2897.|Int J Biol Sci. 2022 Feb 7;18(4):1724-1736.|Int J Clin Exp Pathol. 2017;10(3):3033-3042.|Int J Mol Sci. 2023 Oct 20, 24(20), 15405.|Int J Mol Sci. 2023, 24(2), 1194.|Int J Nanomedicine. 2017 Mar 16;12:2081-2108.|Int J Oncol. 2022 Dec;61(6):148.|International Journal of Biology and Life Sciences. 2023 May 22.|iScience. 2023 Oct 17.|iScience. 6 September 2022, 105064.|iScience. 6 September 2022, 105081.|J Agric Food Chem. June 30, 2022.|J Cell Mol Med. 2023 Jun 29.|J Cell Mol Med. 2019 Sep;23(9):6034-6047.|J Clin Invest. 2018 Jan 2;128(1):483-499. |J Clin Invest. 2024 Mar 7:e172716.|J Drug Target. 2020 Feb;28(2):186-194. |J Electroanal Chem. 2023 Sep 16, 117808.|J Environ Chem Eng. February 2022, 107078.|J Enzyme Inhib Med Chem. 2019 Dec;34(1):117-123. |J Ethnopharmacol. 2020 Jul 15;257:112789.|J Exp Clin Cancer Res. 2018 Sep 19;37(1):232. |J Exp Clin Cancer Res. 2019 Aug 14;38(1):353. |J Food Biochem. 2022 Jan 5;e14065.|J Immunol. 2022 Oct 24;ji2200182.|J Med Chem. 2024 Mar 20.|J Med Virol. 2019 Oct;91(10):1818-1829. |J Nanobiotechnology. 2023 Aug 26;21(1):297.|J Nanobiotechnology. 2024 Mar 26;22(1):132.|J Nanobiotechnology. 2024 Mar 3;22(1):89.|J Nat Prod. 2020 Feb 28;83(2):516-523.|J Pharm Biomed Anal. 2024 Mar 12:243:116097.|J Photoch Photobio B. 2022: 112642.|J Toxicol Sci. 2023;48(8):469-479.|J Transl Med. 2023 Jan 9;21(1):9.|J Transl Med. 2023 Nov 17;21(1):823.|JCI Insight. 2022 Oct 18;e156485.|Life. 2022 Sep 2;12(9):1369.|Mar Drugs. 2022, 20(10), 591.|Mil Med Res. 2021 Dec 9;8(1):63.|Mol Biol Rep. 2022 Nov 9.|Mol Med Rep. 2020 Apr;21(4):1739-1748.|Mol Med Rep. 2020 Jul;22(1):67-76.|Mol Med Rep. 2023 Jan;27(1):17.|Mol Ther. 2023 Feb 18;S1525-0016(23)00079-5.|Molecules. 2020 Feb 14;25(4):836.|Nano Today. 2023 Aug, 51, 101898.|Nanomaterials. 2022, 12(24), 4478.|Nat Commun. 2019 Dec 2;10(1):5492. |Nucleic Acids Res. 2018 Apr 20;46(7):3284-3297.|Nutrients. 2022, 14(19), 4017.|Oncogenesis. 2023 Jun 24;12(1):34.|Oncol Lett. 2020 Jul;20(1):145-154.|Oncol Lett. 2023 Aug 30.|OPT Express. 1976-11986 (2021).|Org Chem Front. 11 Feb 2022.|Patent. US20230145200A1.|PeerJ. 2023 May 18.|Pharmaceutics. 2019 May 27;11(5):247. |Pharmaceutics. 2023 Oct 28, 15(11), 2550.|Pharmacogn Mag. 2023 Apr 14.|Pharmacol Res. 2022 Apr;178:106186.|Phytochemistry. 2022 Jul;199:113172.|Phytomedicine. 2022 Mar 2;99:154027.|Phytomedicine. 2023 Sep 7, 155074.|Phytother Res. 2023 Sep 1.|Plasma Process Polym. 2021 Feb 12.|PLoS One. 2023 Jul 27;18(7):e0288422.|Redox Biol. 18 December 2021, 102219.|Redox Biol. 2022 Jun;52:102310.|Redox Biol. 2024 Mar 19, 103129.|Res Sq. 2024 Aug 11.|Research Square Preprint. 2021 Apr.|Research Square Preprint. 2021 Aug.|Research Square Preprint. 2022 Jun.|Research Square Preprint. 2023 Jun 16.|Research Square Print. November 29th, 2022.|RSC Adv. 2022, 12, 28104-28112.|RSC Med Chem. 2023 Nov 30.|Sci Rep. 2019 Oct 22;9(1):15099. |Sci Rep. 2019 Oct 23;9(1):15172. |Small Methods. 2022 Feb 2;e2101391.|SSRN. 2019 Nov.|Talanta. 2024 Mar 23, 125987.|Theranostics. 2019 Jan 24;9(3):761-777.|Theranostics. 2020 Jul 25;10(21):9477-9494. |Tissue Cell. 2023 Mar 17.|Toxicol Appl Pharmacol. 2022 Jul 29;116179.|Toxics. 2023 Nov 12, 11(11), 925.|Toxins. 2023 Mar 25.|Trop J Pharm Res. 2022; 21 (12): 2541-2548.
• Shipping Conditions: Room Temperature
• Clinical Information: Launched